Two Biologics Show Comparable Benefit in Uveitis

Published Date: 26 Feb 2026

Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.

2.

Cardiopulmonary fitness is key for helping breast cancer patients manage post-diagnosis symptoms, say researchers

3.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.

4.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

5.

WHO launches plan for free child cancer medicines


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot